NEW YORK, Nov. 26-Pyxis Genomics, Inimex Pharmaceuticals and Genome Prairie today announced a new research alliance to study the mechanisms of pathogenic infection.
The $27 million project (US $17.2 million), called "Functional Pathogenomics of Mucosal Immunity", seeks to understand the genetic basis of immunity to infectious disease. Using microarray techniques, researchers will seek to understand disease mechanisms and look for new ways to enhance immunity through preventive treatments and therapies. Two-thirds of the project will focus on veterinary applications of these discoveries.
University of Saskatchewan veterinary microbiologist Lorne Babiuk will lead the project with bacteriologist University of British Columbia's Bob Hancock. Researchers from Simon Fraser University, the British Columbia Cancer Agency, the University of Minnesota and the University of Illinois will also be involved.
Inimex and Pyxis Canada, a subsidiary of Chicago, Ill.-based Pyxis Genomics, will jointly provide $13 million (US $8.2 million) for the effort, and will receive exclusive commercialization rights in return. Pyxis Genomics will retain rights to animal health care discoveries, and Inimex has rights to develop products for human use.
Inimex is a privately held drug discovery and development company in Vancouver, B.C.
Pyxis Genomics, formerly AniGenics, is focused on functional genomics research for improved animal health.
Genome Prairie is a division of Genome Canada, the national quasi-governmental genomics support and funding organization.